Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
- None.
- None.
The Compensation Committee of Aadi's Board of Directors, which is composed entirely of independent directors, approved, as a material inducement to Dr. Lennon entering into employment with Aadi, a grant of a nonstatutory stock option to purchase 490,000 shares of Aadi's common stock (the "Option") under the Plan. The Option has a 10-year term and an exercise price per share equal to
About Aadi Bioscience
Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for genetically defined cancers to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Aadi received FDA approval of FYARRO® in November 2021, and in February 2022 commenced commercialization of FYARRO for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
Aadi is conducting the PRECISION1 trial, a Phase 2 tumor-agnostic registration-directed study in patients with mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on Aadi's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.
Contact:
Marcy Graham
IR@aadibio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-grants-new-ceo-dave-lennon-phd-inducement-award-under-nasdaq-listing-rule-5635-c4-301945981.html
SOURCE Aadi Bioscience